Lek signs strategic cooperation agreement with three major universities in Slovenia
- Lek and three public Slovenian universities have signed a strategic cooperation agreement geared towards deepening cooperation in education, research, and innovation.
- The official signing was followed by a symbolic signing at the Scientific Excellence at the Intersection of Generations event, where Lek scholarships were also awarded.
- Lek has been deeply involved in the Slovenian scientific and research community for decades, and works closely with various educational institutions.
Lek, a Sandoz company, has signed a strategic cooperation agreement with representatives of the University of Ljubljana, the University of Maribor, and the University of Primorska, which will further strengthen cooperation in the fields of education, scientific research, development, and strategy, with the aim of fostering innovation and the development of young talent.
Key areas of cooperation include setting up practical training for students, participation in their final theses, and the involvement of Lek experts in the study process as guest lectures. The agreement also provides for joint applications to Slovenian and international tenders, for the development of research projects and innovations, and for the strengthening of both new and existing study programmes. Cooperation will also take place in the field of lifelong learning, organising joint events such as summer schools, hackathons, and information days.
Gregor Makuc, Lek's Chief Executive Director, stressed at the signing of the agreement that dialogue and cooperation between educational institutions and the pharmaceutical industry is of key importance: "The agreement will make the cooperation between Lek and universities even closer, as we are creating an ecosystem that enables the transfer of knowledge and experience. The pooling of resources, knowledge, and technologies made possible by long-term collaboration will significantly strengthen the innovation capacity of all partners involved, and will be a catalyst for breakthrough scientific advances that will expand access to advanced, effective, safe treatment options for patients around the world. The agreement also brings new opportunities for young talent to take part in ambitious projects and to develop into leading scientists, researchers, and experts, which will key to staying competitive and innovative in the global market in the long term."
Prof. Klavdija Kutnar, Rector of the University of Primorska and President of the Slovenian Rectors' Conference, added, "Public universities are committed to activities and measures aimed at achieving the goals of the National Programme for Higher Education 2030, which emphasises innovation, excellence, increasing quality and – emphasised in light of today's event – responsiveness to the current and future needs of economic and non-economic interests, as well as of the general social environment. With today's signing of a strategic cooperation agreement, Lek d.d. and the public universities recognise their common interest in the development of base knowledge, applied solutions, and innovations, as well as of new ways of working and learning that will enable the development of new talent and competences in line with modern trends. A functioning sustainable ecosystem, which can be built through strategic partnerships with economic operators, is the basis for high quality study programmes and academic development, which is especially important and prominent in the area we all value most – our health."
The present and future of scientific excellence
The official signing of the Strategic Cooperation Agreement at the University of Maribor was followed by a symbolic signing at the Scientific Excellence at the Intersection of Generations event, which brought together the best scientists and most promising young talents in an effort to ensure the further development of science.
Among the keynote speakers was Igor Papič, PhD, Minister of Higher Education, Science, and Innovation, who said in his address, "Today's event brings together science and business, eminent scientists and young talent. Such cooperation serves as a cornerstone of our country's development. And knowing that we are short on staff in the scientific fields, the Ministry is planning measures in this area, including the reintroduction of a tender for researchers in the private sector, as well as measures to attract international students."
One of the highlights of the evening was the awarding of Lek scholarships to promising high school and university students – the new generation of scientists, researchers, and experts who will contribute to the further development of Lek and of the pharmaceutical industry in the future. Eighteen scholarship recipients were presented with their certificates by Nobel Laureate Sir Gregory P. Winter and dr. Jure Vajs, Head of Strategic Programs at Lek.
In the first part of the event, Sir Gregory also took part in a panel discussion with Claire D'Abreu-Hayling, Chief Scientific Officer at Sandoz, on the importance of collaboration and networking between different stakeholders in achieving breakthrough innovation, and the values and personal characteristics needed to achieve excellence.
About Lek
Lek, a Sandoz company, is the first and oldest pharmaceutical company in Slovenia, developing, manufacturing and marketing effective, safe and high-quality generics and biosimilars for patients around the world. Our work is guided by strong ethical standards, innovative thinking and the breakthrough achievements of our world-class professionals. With more than 3,700 associates, we have been actively shaping the Slovenian, European and global research and development landscape for decades. We are building a culture of open dialog, and we proudly and responsibly hold the title of most reputable employer in Slovenia.
About Sandoz
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 800 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the first biosimilar in 2006. In 2023, Sandoz recorded sales of USD 9.6 billion.
Disclaimer
This Media Release contains forward-looking statements which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.